Immunomodulatory News and Research

RSS

From turmeric to fenugreek, scientists examine nature’s potential role in diabetes care

A narrative review examined how curcumin, honey, culinary spices, and traditional remedies may influence oxidative stress, inflammation, mitochondrial function, and insulin signaling in diabetes. Although experimental research and some clinical trials suggest potential metabolic benefits, the authors emphasize that larger, well-controlled studies are needed to establish their effectiveness and safety alongside conventional treatments.

14 Oct 2026

Human dental pulp stem cell secretome boosts stroke recovery

Ischemic stroke can leave lasting neurological damage after the initial vascular event, with oxidative stress, neuroinflammation, neuronal death, and disruption of neural connectivity contributing to impaired recovery.

6 Oct 2026

Family history of type 1 diabetes may shape how you see your own risk

Understanding type 1 diabetes risk among first-degree relatives is influenced by personal beliefs and family experiences, affecting screening interpretations.

6 Oct 2026

New mathematical model tracks how tumor environment impacts cancer therapies

Researchers from Mass General Brigham and the University of Cyprus have developed a sophisticated mathematical model to better understand how the tumor microenvironment affects the delivery and effectiveness of a new type of cancer therapy called an immunomodulatory antibody-drug conjugate (IM-ADC).

30 Sep 2026

Could the Mediterranean diet protect the brain through the gut?

A narrative review finds that the Mediterranean diet may support brain health through gut microbiome, immune, metabolic, and barrier-related pathways, but direct human evidence that microbiome remodeling mediates neuroprotection remains limited. The proposed mechanisms involve microbial metabolites, reduced inflammatory signaling, stronger intestinal and blood-brain barrier function, and possible effects on processes linked to Alzheimer’s and Parkinson’s diseases.

27 Sep 2026

EGFR co-targeting and nanotechnology offer new triple-negative breast cancer therapies

Triple-negative breast cancer (TNBC) remains one of the most challenging forms of breast cancer to treat because it lacks the estrogen, progesterone and HER2 receptors that enable targeted treatment in other breast cancer subtypes.

24 Sep 2026

Salt-purified seaweed compound suppresses inflammatory and allergic reactions

Food allergies affect an estimated 3%–4% of the global population, yet no definitive cure is currently available.

22 Sep 2026

Marine carbohydrates offer valuable new resources for drug development

The ocean contains diverse carbohydrates that could serve as valuable resources for drug development. Algae, marine animals and microorganisms produce polysaccharides and related molecules with structures that are uncommon on land, including distinctive sulfate patterns, sugar linkages and branched architectures.

22 Sep 2026

Sex-specific biological clocks reveal how aging differs across the body in women and men

Researchers developed 38 sex-specific biological aging clocks across 15 organ systems, finding differences between females and males in genetic architecture, molecular signatures, disease associations, and mortality patterns. Brain aging clocks were linked to progression from mild cognitive impairment to Alzheimer’s disease in both sexes and to sex-dependent cognitive trajectories among solanezumab-treated A4 participants, while the authors stressed that sex-pooled and sex-interaction models remain complementary approaches.

17 Sep 2026

Cannabis-derived nanovesicles showed early antitumor potential in mice

Researchers developed a Cannabis sativa hairy root culture system that produced stable plant-derived nanovesicles capable of promoting dendritic cell maturation and activating T-cell responses through TLR2- and TLR4-associated signaling. Oral administration also restored selected immune responses in immunosuppressed mice and suppressed tumor growth in an E.G7 lymphoma model, providing preliminary evidence for their immunomodulatory and antitumor potential.

15 Sep 2026

COVID-19 linked to lower subsequent risk of type 1 diabetes

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows that people who have had COVID-19 have a lower, rather than higher, risk of subsequent development of type 1 diabetes (T1D).

8 Sep 2026

Could scorpion venom inspire new treatments for liver disease?

Scorpion venom peptides show promising anti-inflammatory, antiviral, analgesic, and immunomodulatory effects, with experimental evidence suggesting that some candidates could target pathways involved in chronic liver disease and viral hepatitis. The review highlights Kv1.3-blocking peptides and antiviral compounds as potential therapeutic leads, while emphasizing that limited hepatic efficacy data, poor pharmacokinetics, immunogenicity, and manufacturing challenges must be overcome before clinical translation.

8 Sep 2026

Dual-drug microneedle patch targets inflammation and fat browning

The worldwide obesity crisis has become a dominant public health crisis across the globe. Over 3 billion people worldwide currently suffer from obesity, and forecasts warn the number will rise above 4 billion by 2035, accounting for more than half the global population.

4 Sep 2026

Pomegranate phytobiotics offer natural alternative to synthetic veterinary drugs

Researchers have identified a broad range of biological properties in pomegranate with potential for use in medical applications, including antimicrobial, antiparasitic, antioxidant, immunomodulatory, antidiabetic, anti-inflammatory, liver-supporting, and wound-healing effects.

27 Aug 2026

Study finds distinct patterns of innate immune activity in mental disorders

The immune system may also play a role in mental disorders. Scientists are investigating these links with brain function in greater detail, and new findings show that immune changes may differ by disorder type.

25 Aug 2026

What decades of wine research can, and cannot, tell us about health

A narrative review found that moderate wine intake has repeatedly been associated with lower all-cause and cardiovascular mortality, with proposed mechanisms involving ethanol and grape-derived polyphenols, but the evidence remains largely observational and cannot establish causation. The authors argue that drinking pattern, beverage type, age, cancer risk, and risk-modeling choices all influence how the J-shaped association should be interpreted and how alcohol guidelines are developed.

25 Aug 2026

Researchers link GLP-1 drugs to lower tuberculosis risk in type 2 diabetes

A large retrospective cohort study found that GLP-1 receptor agonist use was associated with a lower risk of tuberculosis in people with type 2 diabetes compared with sulfonylureas, metformin, DPP-4 inhibitors, and SGLT2 inhibitors. The observational findings suggest a possible benefit beyond metabolic control, but the authors emphasize that prospective and mechanistic studies are needed to determine whether GLP-1 therapies themselves reduce TB risk.

24 Aug 2026

Gene editing fails to protect beta-cell transplants from rejection

In people with type 1 diabetes, the immune system mistakenly destroys the pancreatic beta cells responsible for producing insulin. Patients therefore require lifelong insulin therapy to regulate their blood glucose levels.

19 Aug 2026

Molecular mapping reveals hidden cellular programs in heart transplant rejection

A new study that explores gene expression during heart transplant rejection marks a step forward for precision medicine approaches to treat organ rejection.

12 Aug 2026

New research agreement funds xenoliver transplant center at Baylor

Baylor College of Medicine today announced that a new research agreement with United Therapeutics Corporation, a public benefit corporation, will provide up to $5 million a year for five years to establish the Baylor College of Medicine Center for Xenoliver Transplantation and Immunomodulation (XTI), dedicated to advancing scientific understanding of xenoliver transplantation.

10 Aug 2026